We Have a Track Record of Creating Value for Our Partners
Selected Publicly Announced Investments
Humacyte is developing universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine.
Helsinn is a fully integrated global biopharma company headquartered in Lugano, Switzerland. The Company is focused on improving the lives of cancer patients all over the world with a leading position in cancer supportive care and a focus on cancer therapeutics and rare diseases.
Zealand Pharma is a biotechnology company focused on the discovery and development of peptide-based medicines. The company has development partnerships with a number of pharma companies as well as commercial partnerships for its marketed products.
Centessa Pharmaceuticals is a clinical-stage pharmaceutical company that aims to discover and develop medicines that are transformational for patients. Centessa’s programs span discovery-stage to late-stage development and cover a range of high-value indications.
Mirum Pharmaceuticals is a biopharmaceutical company dedicated to transforming the treatment of rare liver diseases. Mirum’s approved medication is LIVMARLI® (maralixibat) oral solution, which is approved in the U.S. for the treatment of cholestatic pruritus in patients with Alagille syndrome three months of age and older.
Axogen is focused on the science, development, and commercialization of technologies for peripheral nerve regeneration and repair. Axogen's platform for peripheral nerve repair features a comprehensive portfolio of products that are used across two primary application categories: scheduled, non-trauma procedures and emergent trauma procedures.
Esperion Therapeutics is a pharmaceutical company focused on developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol ("LDL-C").
NorthStar Medical Radioisotopes is a commercial-stage nuclear medicine company focused on advancing patient care by providing diagnostic and therapeutic radioisotopes, novel radiopharmaceuticals and customized radiopharmaceutical development services.
Invitae is a medical genetics company offering high-quality, comprehensive, affordable genetic testing across multiple clinical areas, including hereditary cancer, precision oncology, women's health, and rare disease.
Acquired by Celgene Corporation.
Agenus is an immuno-oncology company targeting cancer and infectious diseases with a comprehensive pipeline of immunological agents. The company’s mission is to expand patient populations benefiting from cancer immunotherapy through combination approaches, using a broad repertoire of antibody therapeutics, adoptive cell therapies and adjuvants.
Oxford Biomedica is a quality and innovation-led viral vector CDMO with a mission to enable its clients to deliver life changing therapies to patients around the world.
Referenced companies do not represent an entire fund or portfolio.